Longevity Is Now a Subscription Service — If You Can't Pay the Fee, You Get Cancelled Early
The longevity gap has emerged as the 21st century's most insidious form of class stratification, quietly transforming human lifespan into a purchasable commodity available only to those with sufficient capital. In the United States, the life expectancy divide between the top and bottom 1% of income earners stands at 14.6 years for men and 10.1 years for women, and multi-factor socioeconomic modeling reveals this chasm can reach 24 full years when education, income, and accumulated wealth are combined (CEPR). Billionaires are accelerating this divergence by committing unprecedented capital to anti-aging biotech: Bryan Johnson spends $2 million annually on personal life-extension protocols, Jeff Bezos has invested $3 billion into cellular reprogramming lab Altos Labs, and Sam Altman committed his entire liquid net worth — $180 million — to Retro Biosciences, a company now valued at $1.8 billion. A 27-year gap already separates the Central African Republic (life expectancy 57.67 years, WHO 2024) from Japan (84.95 years), demonstrating that longevity inequality is not a future risk but an active, ongoing structural reality that anti-aging technology threatens to deepen. Since lifespan is the compound-interest timer of wealth accumulation and the operational duration of political influence, the deepening longevity divide represents not merely a public health crisis but a foundational threat to the conditions required for genuine democratic equality.